Back to search results

T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

B-Cell Non-Hodgkin's Lymphoma (NHL) · Lymphoma, Non-Hodgkins · Lymphomas Non-Hodgkin's B-Cell · Non-Hodgkin Lymphoma · Non-Hodgkin's Lymphoma · Large B-Cell Lymphoma · Lymphoma, Non-Hodgkin's, Adult · Lymphoma · Refractory Non-Hodgkin Lymphoma · Relapsed Non-Hodgkin Lymphoma · Lymphoma, Non-Hodgkin · HIV Associated Lymphoma · CNS Lymphoma · High-grade B-cell Lymphoma · Refractory B-Cell Non-Hodgkin Lymphoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • University of California, Davis, Sacramento, California, United States

    Contact: Study coordinator (Richard "RJ" Joven, CCRP) · rmjoven@ucdavis.edu · 916-494-2368
    Contact: Study coordinator (Dara Feleciano, RN, MSN) · djfeleciano@ucdavis.edu · 916-475-9904
    Contact: Principal Investigator (Naseem Esteghamat, MD MS)
    Mehrdad Abedi, MD (Sub-investigator)

  • Baylor Scott & White Research Institute, Texas Oncology, Dallas, Texas, United States

    Contact: Study coordinator (Philip Millsap) · corchemebmt@BSWHealth.org · 214-820-7381
    Contact: Principal Investigator (Luis Pineiro, MD)
Study leads

  • Pei Wang, PhD

    Study Director

    Eureka Therapeutics Inc.

View source on ClinicalTrials.gov(opens in a new tab)